Dr. Rhie received a B.S. in Biochemistry, magna cum laude from the University of California, Los Angeles, and earned a Ph.D. in Genetic, Molecular, and Cellular Biology from the University of Southern California in 2013. She completed postdoctoral training in the laboratories of Dr. Peter Laird and Dr. Peggy Farnham. Dr. Rhie has participated in genome-wide association studies for various cancer types, unraveling mechanisms that explain how genetic variants affect disease risks. She has characterized heterogeneous tumor tissues through DNA methylation analysis with the Cancer Genome Atlas Consortium, discovering genetic alterations such as somatic mutations, fusions, and copy number variations associated with epigenetic changes in cancer. Currently, her research focuses on characterizing key transcription factors and understanding the roles of regulatory elements activated in different types of cancers and neurodevelopmental diseases. Dr. Rhie's lab utilizes molecular biology and bioinformatics to investigate genes regulated by the 3D nucleome structure, employing techniques including ChIP-seq, RNA-seq, whole genome sequencing, CRISPR/Cas9, among others, to discover new molecular mechanisms for human diseases and aid in the development of therapeutics to enhance the quality of life for patients.